Clal Insurance Enterprises Holdings Ltd Has $62.61 Million Stock Position in Cellebrite DI Ltd. $CLBT

Clal Insurance Enterprises Holdings Ltd grew its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 17.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 3,913,014 shares of the company’s stock after acquiring an additional 570,000 shares during the quarter. Clal Insurance Enterprises Holdings Ltd’s holdings in Cellebrite DI were worth $62,608,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of CLBT. Assetmark Inc. acquired a new stake in Cellebrite DI in the 1st quarter valued at $33,000. Signaturefd LLC boosted its stake in shares of Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock valued at $32,000 after purchasing an additional 819 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Cellebrite DI by 1,998.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after purchasing an additional 1,998 shares during the last quarter. Virtus Advisers LLC acquired a new stake in shares of Cellebrite DI during the 1st quarter worth about $63,000. Finally, Hennessy Advisors Inc. acquired a new stake in shares of Cellebrite DI during the 2nd quarter worth about $83,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Trading Up 0.7%

Cellebrite DI stock opened at $18.30 on Wednesday. The company has a market cap of $4.38 billion, a PE ratio of -24.08, a PEG ratio of 3.16 and a beta of 1.28. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The company’s 50-day moving average is $17.86 and its two-hundred day moving average is $16.63.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $126.03 million for the quarter, compared to the consensus estimate of $122.98 million. During the same period last year, the firm earned $0.14 earnings per share. The company’s quarterly revenue was up 17.9% on a year-over-year basis. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on CLBT shares. Needham & Company LLC upped their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. increased their price target on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Lake Street Capital raised their price target on Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, Bank of America boosted their price objective on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cellebrite DI has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.